Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Sep 07, 2021

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

Aug 19, 2021

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

Aug 10, 2021

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Jul 28, 2021

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

Jul 06, 2021

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

Jun 16, 2021

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

May 12, 2021

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

Apr 29, 2021

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021

Apr 27, 2021

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Mar 16, 2021

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 31 - 40 of 92

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2023 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy